TAAR1 agonists and ulotaront in schizophrenia and related psychiatric indications

Landscape of the field taar1-schizophrenia, mapped through the Amass MCP. Generated 2026-10-09 after run update-1. Every figure on this page is computed from the ledgers.

Drug records in scope
3
0 unsure, 52 screened out
Gene records in scope
1
0 unsure, 2 screened out
Trials in scope
52
4 unsure, 319 screened out
Papers in scope
159
6 unsure, 63 screened out
Authorizations in scope
0
0 unsure, 20 screened out
Patent records in scope
45
13 unsure, 115 screened out

What changed in run update-1

Nothing new in the field and no change on a tracked column.

Not due this run: BiomedCore, PatentCore.

Pipeline

Trials by phase, per drug

Registry records in scope; a trial registered twice counts twice, a record naming two drugs counts under both.

Phase 1Phase 2Phase 3Other or not stated
01020304050ulotarontulotaront: Phase 1 13ulotaront: Phase 2 4ulotaront: Phase 3 14ulotaront: other 1243ralmitarontralmitaront: Phase 1 3ralmitaront: Phase 2 2ralmitaront: other 49

Trial activity, per drug

Active: recruiting, not yet recruiting, enrolling by invitation, active not recruiting. Stopped: terminated, withdrawn, suspended. Other statuses are not plotted.

ActiveCompletedStopped
01020304050ulotarontulotaront: active 14ulotaront: completed 24ulotaront: stopped 341ralmitarontralmitaront: completed 6ralmitaront: stopped 17

Papers per year

In-scope papers by publication year; the current year is partial.

01020302012: 420122013: 12014: 520142015: 52016: 720162017: 22018: 420182019: 92020: 520202021: 202022: 1720222023: 212024: 232024232025: 172026: 15202615

Patent families per priority year

One count per family, by the earliest priority date in scope.

05102012: 220122013: 12014: 220142016: 2201620182020: 220202021: 992022: 820222023: 22024: 320242026
Table view of the two charts above
Papers per yearCount
20124
20131
20145
20155
20167
20172
20184
20199
20205
202120
202217
202321
202423
202517
202615
Patent families per priority yearCount
20122
20131
20142
20150
20162
20170
20180
20190
20202
20219
20228
20232
20243
20250
20260

By entity

A record naming two drugs counts under both. A target entity counts gene records, papers and patents, not trials. A class entity takes the records that name no drug or target.

EntityKindTrialsPhase 3Phase 2Phase 1ActiveCompletedStoppedWith resultsPapersPapers, last 24 monthsPatent familiesAuthorizationsDrug records
ulotarontdrug43144131424311396702
ralmitarontdrug9023061421001
selutarontdrug0000000011000
LK00764drug0000000010000
AP163drug0000000010000
PCC0105004drug0000000011000
TAAR1target00000000111231500
TAAR1 agonistsclass0000000063300
Unassigned000000002041800

Briefing

TAAR1 agonists in schizophrenia: landscape briefing

Field taar1-schizophrenia, mapped through the Amass MCP on 2026-10-08. Every number below comes from the run summary (log/summary-baseline-1.md), which the helper computed from the ledgers.

The field in three sentences

TAAR1 agonism in psychiatry is a two-drug clinical field: ulotaront (SEP-363856) carries the development programme, ralmitaront's programme has stopped, and four newer agonists named in the literature (selutaront, LK00764, AP163, PCC0105004) have no trial record yet. The map holds 52 in-scope trial records, 159 papers, 45 patent families, 3 drug records and the TAAR1 gene record; the target-level literature alone has 23 papers from the last 24 months. No TAAR1 agonist is approved anywhere, so there is no authorization to track yet.

By drug

EntityKindTrialsPhase 3Phase 2Phase 1ActiveCompletedStoppedWith resultsPapersPapers, last 24 monthsPatent familiesAuthorizationsDrug records
ulotarontdrug43144131424311396702
ralmitarontdrug9023061421001
selutarontdrug0000000011000
LK00764drug0000000010000
AP163drug0000000010000
PCC0105004drug0000000011000
TAAR1target00000000111231500
TAAR1 agonistsclass0000000063300
Unassigned000000002041800

Ulotaront. 43 trial records, of which 14 are Phase 3, 4 Phase 2 and 13 Phase 1; 14 are active and 24 completed, 3 stopped, and 11 have posted results. The trial records include registrations of the same study in several registries (an NCT record and a Japanese jRCT record for one trial, for instance), which is why the count is of records rather than studies. 39 papers name the drug, 6 of them from the last two years, and 7 patent families cover it. DrugCore holds two records, the base compound and its hydrochloride.

Ralmitaront. 9 trial records, 2 Phase 2 and 3 Phase 1, none active: 6 completed, 1 stopped, 4 with results. Two papers and one drug record; no patent family names it.

Newer agonists. Selutaront, LK00764, AP163 and PCC0105004 each appear in one paper and in no trial. They have no DrugCore record yet, which is how ChEMBL-anchored data treats compounds this new; their names are in the plan, so a registered trial will be picked up by the next update.

Target-level work. 111 papers and 15 patent families are about TAAR1 as a target without naming one of these drugs, 23 of the papers from the last two years. 20 papers and 18 patent families match neither a drug nor the target by name (class reviews, generic patent titles) and are listed under Unassigned on the Landscape sheet.

Authorizations

None. No TAAR1 agonist holds an FDA or EMA authorization; the 20 RegulatoryCore records the searches returned are other products whose label text mentions an agonist, and all are screened out with that reason.

Coverage

All three anchor trials were found by search, including the Japanese trial under both its NCT and jRCT registrations. Of the 32 trials linked from the ulotaront and ralmitaront drug records, the searches had reached every one. On TrialCore the code, mechanism and sponsor facets saturated; the drug facet, and the paper and patent facets, were still producing when the run ended, so a later "extend" would add papers and patents before it adds trials. 23 records are unsure and need a call: 4 trials whose records do not state the mechanism (two SEP-380135 trials, one SEP-479, one VV119), 6 papers at the boundary of the scope (broad reviews and trace-amine physiology), and 13 patents, among them a likely ulotaront use patent whose abstract never names TAAR1.

How to use the files

The workbook taar1-schizophrenia.xlsx opens on the Landscape sheet: the table above, the scope, the coverage box and these instructions. Key records lists the Phase 2 and later trials and the authorizations, one line each. The Core sheets (TrialCore, BiomedCore, DrugCore, GeneCore, RegulatoryCore, PatentCore) hold every in-scope and unsure record with its decision and reason; filter on the decision column to see the unsure ones. Excluded holds everything that was screened out, with the reason. The folder landscapes/taar1-schizophrenia is the memory for updates, so keep it; say "run the update" to get what changed since this map, by drug and by Core. The in-scope trials can also be exported as a watchlist for amass-watchlist-monitor, which tracks those records exactly.

Key records

20 Phase 2 and later trials, 0 authorizations
DrugTrialPhaseStatusSponsorStartEnrolmentResults
ulotarontNCT06894212
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
PHASE3ACTIVE_NOT_RECRUITINGOtsuka Pharmaceutical Development & Comm2025-02-28538
ulotarontNCT07225712
A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia
PHASE3RECRUITINGOtsuka Pharmaceutical Co., Ltd.2025-12-22100
ulotarontNCT07759128
A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder
PHASE3RECRUITINGOtsuka Pharmaceutical Development & Comm2026-07-28576
ulotarontNCT07767903
A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder
PHASE3RECRUITINGOtsuka Pharmaceutical Development & Comm2026-08-06384
ulotarontNCT07786454
A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder
PHASE3NOT_YET_RECRUITINGOtsuka Pharmaceutical Development & Comm2026-10-061120
ulotarontNCT04072354
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With
PHASE3COMPLETEDOtsuka Pharmaceutical Development & Comm2019-09-17463yes
ulotarontNCT04092686
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic Peopl
PHASE3COMPLETEDOtsuka Pharmaceutical Development & Comm2019-10-14464yes
ulotarontNCT04109950
A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With S
PHASE3TERMINATEDOtsuka Pharmaceutical Development & Comm2019-11-20463
ulotarontNCT04115319
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
PHASE3COMPLETEDOtsuka Pharmaceutical Development & Comm2019-11-21305yes
ulotarontNCT05359081
A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophreni
PHASE3TERMINATEDSumitomo Pharma Co., Ltd.2022-05-1668
ulotarontNCT05628103
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia
PHASE3COMPLETEDOtsuka Pharmaceutical Development & Comm2022-12-19101yes
ulotarontNCT05741528
An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-3638
PHASE3COMPLETEDOtsuka Pharmaceutical Development & Comm2023-03-3175yes
ulotarontNCT04825860
A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophre
PHASE2/PHASE3TERMINATEDSumitomo Pharma Co., Ltd.2021-03-2983
ulotarontNCT05729373
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anx
PHASE2/PHASE3COMPLETEDOtsuka Pharmaceutical Development & Comm2023-03-08434
ulotarontNCT02969382
A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
PHASE2COMPLETEDOtsuka Pharmaceutical Development & Comm2016-12-05245yes
ulotarontNCT02969369
A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease P
PHASE2COMPLETEDOtsuka Pharmaceutical Development & Comm2016-12-3139yes
ulotarontNCT02970929
An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia
PHASE2COMPLETEDOtsuka Pharmaceutical Development & Comm2017-01-31157yes
ralmitarontNCT03669640
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective
PHASE2TERMINATEDHoffmann-La Roche2018-12-04131yes
ralmitarontNCT04512066
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerb
PHASE2COMPLETEDHoffmann-La Roche2020-09-08287yes
ulotarontNCT05593029
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder
PHASE2COMPLETEDOtsuka Pharmaceutical Development & Comm2022-11-09929

No authorization in scope: no drug of this field holds an FDA or EMA authorization in Amass.

Coverage

Anchor records found by search
3 of 3
records that had to be in the field
Linked BiomedCore reached by search
1 of 1
0 only by fetch, 0 open, 0 out of scope by design
Linked GeneCore reached by search
1 of 2
0 only by fetch, 0 open, 1 out of scope by design
Linked TrialCore reached by search
32 of 32
0 only by fetch, 0 open, 0 out of scope by design
Linked DrugCore reached by search
1 of 1
0 only by fetch, 0 open, 0 out of scope by design
Search facets
6 / 16
saturated, of those run
Unsure records
23
4 TrialCore, 6 BiomedCore, 13 PatentCore

Saturated: DrugCore drug, TrialCore code, TrialCore mechanism, TrialCore sponsor, BiomedCore drug, RegulatoryCore drug. Still producing when the run ended: DrugCore mechanism, DrugCore target, GeneCore target, TrialCore drug, BiomedCore code, BiomedCore mechanism, RegulatoryCore mechanism, PatentCore mechanism, PatentCore drug, PatentCore sponsor.

Search is relevance-ranked and capped per call, so the map is as complete as the plan and its saturation say. Date-filtered searches cannot see deletions, results-only revisions, label or SmPC section-only revisions, or in-place publication-date corrections; PatentCore updates find newly published patents only.

Scope

How to use the files